Palopegteriparatide,
does it really help with Maintained corrected normocalcemia while eliminating active vitamin D and reducing calcium supplementation in chronic hypoparathyroidism?
research showsThe grade is C. PaTHway randomized 84 participants but analyzed the 82 who received treatment, 61 active and 21 placebo. At week 26, the composite of corrected normocalcemia, no active vitamin D, calcium at or below 600 mg/day, and no study-dose increase during the final four weeks occurred in 48/61 (79%) versus 1/21 (5%), an absolute difference of 74 points (P<0.0001). The effect is large, but this is a surrogate composite in one manufacturer-funded trial with fewer than 200 participants, giving C with 50 points.
ads claimMaintaining calcium while reducing supplements is real, but it is not evidence of fewer fractures, kidney disease, hospitalizations, or deaths at 26 weeks. Marketing should disclose that this was one small trial within the manufacturer's development program.
Useful facts when choosing a product
- Ninety-three percent, 57/61, achieved no active vitamin D and calcium at or below 600 mg/day.
- The absolute primary composite-response difference was 74 points.
- The drug and dedicated pen were manufacturer-developed tested products, and the company designed and funded the trial.
What the research actually shows
PaTHway was a 26-week double-blind placebo-controlled phase 3 trial at 21 North American and European sites. Eighty-four participants were randomized 3:1; two assigned to active treatment stopped before dosing, leaving the prespecified treated intention-to-treat and safety population of 82, 61 versus 21. Sixty active and 19 placebo participants, 79 total, completed week 26. The drug and modified Ypsomed UnoPen were tested products. The article states, "This study was funded by Ascendis Pharma Bone Diseases A/S." Company employees participated in design, analysis, and manuscript preparation. Verdict 963 is A with 88 points for replacing deficient cortisol in primary adrenal insufficiency, a different disease and hormone. Verdict 2748 is D with 34 points for parathyroidectomy and long-term events in mild primary hyperparathyroidism, an opposite functional disorder and different intervention.
Why this is classified as C (50)
The composite response difference was very large, but surrogate focus, one 82-participant manufacturer trial, and small size give C with 50 points.
Counterpoint. Reduced supplement burden may matter, but long-term fracture, renal, cardiovascular, and safety outcomes require separate follow-up.
Rejudgment record. Cross-check applied — Recognizes the 74-point composite-response difference in 82 treated participants while accounting for surrogate, manufacturer-only, single-trial, and small-sample limitations
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Week-26 composite independence from conventional therapy | C | The large 79% versus 5% difference came from one manufacturer trial using a surrogate composite. |
| Reduced long-term fracture or renal events | ? | The 26-week trial did not test those event benefits. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Twenty-one-site 3:1 double-blind randomized placebo-controlled phase 3 trial | 79 | Funded and designed by Ascendis Pharma Bone Diseases A/S; study drug and dedicated pen were tested products | Week-26 composite of corrected normocalcemia, no active vitamin D, calcium at or below 600 mg/day, and stable study dose during the final four weeks | 48/61 (79%) versus 1/21 (5%); absolute difference 74 points, P<0.0001 | Single small manufacturer-funded confirmatory trial with a surrogate composite |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Palopegteriparatide x independence from conventional therapy in chronic hypoparathyroidism — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/palopegteriparatide-chronic-hypoparathyroidism-conventional-therapy-independence/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.